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Psychostimulants show therapeutic efficacy in the treatment of attention-deficit
hyperactivity disorder (ADHD). It is generally assumed that they ameliorate ADHD
symptoms via interfering with monoaminergic signaling. We combined behavioral
pharmacology, neurochemistry and molecular analyses to identify mechanisms
underlying the paradoxical calming effect of amphetamine in low trait anxiety behavior
(LAB) mice, a novel multigenetic animal model of ADHD. Amphetamine (1 mg/kg) and
methylphenidate (10 mg/kg) elicited similar dopamine and norepinephrine release in
the medial prefrontal cortex (mPFC) and in the striatum of LAB mice. In contrast,
amphetamine decreased, while methylphenidate increased locomotor activity. This
argues against changes in dopamine and/or norepinephrine release as mediators
of amphetamine paradoxical effects. Instead, the calming activity of amphetamine
corresponded to the inhibition of glycogen synthase kinase 3β (GSK3β) activity,
specifically in the mPFC. Accordingly, not only systemic administration of the GSK3β
inhibitor TDZD-8 (20 mg/kg), but also local microinjections of TDZD-8 and amphetamine
into the mPFC, but not into the striatum, decreased locomotor activity in LAB mice.
Amphetamine effects seem to depend on NMDA receptor signaling, since pre- or co-
treatment with MK-801 (0.3 mg/kg) abolished the effects of amphetamine (1 mg/kg)
on the locomotion and on the phosphorylation of GSK3β at the level of the mPFC.
Taken together, the paradoxical calming effect of amphetamine in hyperactive LAB
mice concurs with a decreased GSK3β activity in the mPFC. This effect appears to be
independent of dopamine or norepinephrine release, but contingent on NMDA receptor
signaling.
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Introduction
Attention deficit hyperactivity disorder (ADHD) is a frequent psychiatric disorder
with a prevalence of up to 8% in Western populations (Faraone and Mick, 2010). It
appears in three types of presentation (inattentive, hyperactive/impulsive, and combined)
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and shows a high degree of psychiatric comorbidity, e.g., with
unipolar depression and autism spectrum disorder (Faraone
et al., 2006; Piñeiro-Dieguez et al., 2014). It is generally assumed
that alterations in the monoamine signaling are causally
involved in the etiology of ADHD. This assumption is based
on a paradoxical therapeutic efficacy of monoamine releasing
drugs (amphetamine and methylphenidate and selective
norepinephrine re-uptake inhibitor reboxetine) in the treatment
of ADHD. Presynaptic dopamine D2 receptor-mediated
downregulation of dopamine release resulting from a transient
initial increase was assumed as the underlying mechanism of the
paradoxical effect (Seeman and Madras, 1998).
Despite a conceivable involvement of the striatum, which
mediates the dopamine-dependent locomotion, clinical evidence
and effectiveness of cognitive therapy nourish the idea that
the prefrontal cortex (PFC) rather than the striatum plays
a critical role in ADHD pathogenesis and therapy (Mattes,
1980; Barkley, 1997). This is confirmed with recent functional
imaging data showing the frontal hypoactivity in patients
with ADHD (Dickstein et al., 2006). The impairment of N-
methyl-D-aspartate (NMDA) receptor signaling in the medial
PFC (mPFC) is believed to underlie the frontal hypoactivity
and the insufficient control over vigilance and executive
functions in ADHD. Disturbance in the norepinephrine and
dopamine cortical neurotransmission may mediate the NMDA
receptor signaling shortage (Makris et al., 2009; Arnsten and
Pliszka, 2011). This suggests postsynaptic mechanisms including
intracellular signaling pathways asmediators of hyperactivity and
the paradoxical action of dopamine-releasing drugs.
Glycogen synthase kinase 3β (GSK3β) was primarily
identified as a glycogen synthase inhibiting enzyme, a key in the
glucose metabolism regulation. It also interacts with β-catenin
and is intimately involved in processes of neurogenesis and
neuroprotection. The non-canonical β-arrestin2/PP2A/Akt-
-GSK3β pathway plays a significant role in the mediation
of dopamine D2/3 receptor- and amphetamine-dependent
behavior. Dopamine release and activation of dopamine D2
receptors result in a decrease in the Akt activity and respective
decrease in GSK3β phosphorylation leading to its activation
(Beaulieu et al., 2004, 2005). Both pharmacologically-induced
and innate experimental hyperactivity can be temporarily
recovered by GSK3β inhibition (Emamian, 2012; Mines et al.,
2013). Changes in the state of constitutionally active GSK3βwere
considered as both pathogenetic factor and therapeutic means
in bipolar disorder and schizophrenia (Jope and Roh, 2006;
Emamian, 2012). Accordingly, antipsychotics inhibit GSK3β
(Emamian et al., 2004; Li et al., 2007).
GSK3β is subject to plenty of upstream regulators acting
via β-arrestin2/Akt and Wnt/β-catenin, DAG/Ca2+-PKC, Trk
R/insulin R/BDNF R-PI3K/PDK1, and PPI1-mediated pathways.
Recent findings showed that not only dopamine, but also
serotonin, adenosine, and brain-derived neurotrophic factor
are among these upstream regulators (Jope and Roh, 2006;
Kaidanovich-Beilin and Woodgett, 2011). The intracellular
pathways, which can be activated by NMDA receptors, also target
GSK3β (Svenningsson et al., 2003; Peineau et al., 2007; Li et al.,
2009; Beurel et al., 2011; Xi et al., 2011; Liu et al., 2013).
Animal models of ADHD may help to further elucidate
the biological basis of the disorder and provide deeper insight
into the processes underlying effective therapeutic intervention.
Most ADHD models are based on selected mutations in
monoaminergic systems (Russell, 2011; Leo and Gainetdinov,
2013). However, selective breeding strategiesmay better resemble
the multigenetic background of the disorder. We have recently
validated a novel inbred ADHD mouse model, i.e., low trait
anxiety-related behavior (LAB) mice (Yen et al., 2013). LAB
mice were originally bred contrasting normal trait anxiety-
related behavior (NAB) and high trait anxiety-related behavior
(HAB) mice (Krömer et al., 2005). Selection was based on
mouse exploratory behavior on the elevated plus-maze. LAB
mice display a clear preference for the open arms (>60%),
whereas NAB spend 20--40% and HAB <20% of the total
time in the open arms. The open arm preference cannot be
solely explained by low anxiety levels, but seems to reflect
the increased novelty seeking (Yen et al., 2013). LAB mice of
both genders show hyperactivity both in home cages (Krömer
et al., 2005) and in the open field (OF; Yen et al., 2013).
Remarkably, this hyperactivity becomes even stronger upon
repeated exposures, thus arguing against a novelty-driven
phenomenon (Yen et al., 2013). LAB mouse endophenotype
is characterized by an increase in acoustic startle responses,
impaired social recognition and spatial memory. Compared to
HAB mice, LAB mice display changes in metabolic pathways
both in the periphery and in the brain (Krömer et al., 2005;
Kessler et al., 2007; Filiou et al., 2011). In terms of predictive
validity, LAB mice show a paradoxical calming response to
amphetamine in non-toxic doses (0.5--2.0 mg/kg, i.p.) (Yen et al.,
2013).
The aim of the present study was to elucidate the
neurochemical and molecular basis of the paradoxical effect of
amphetamine in our mouse model of ADHD (i.e., LAB mice)
with a special focus on the role of GSK3β. To this end, (1)
we examined locomotor activity in the OF and employed in
vivo microdialysis in order to compare behavioral effects of
amphetamine (and methylphenidate) in LAB and HAB mice
with drug-related changes in the dopamine and norepinephrine
levels in the mPFC and the striatum. We assessed (2) the
efficiency of the dopamine D2 receptor function in LAB mice by
measuring behavioral and neurochemical effects of haloperidol.
We explored (3) the effects of amphetamine treatment on the
phosphorylation of GSK3β in the two brain structures under
study; and (4) the effects of systemic and local inhibition of
GSK3β on locomotor activity. Finally, we examined (5) potential
involvement of glutamate signaling via NMDA receptors in the
mechanisms of the calming effect of amphetamine.
Material and Methods
Animals
Male HAB, LAB and normal trait anxiety-related behavior
(NAB) mice are selectively bred from Swiss CD1 mice (Charles
River, Sulzfeld, Germany) in the Max Planck Institute of
Psychiatry. Hyperactivity of LAB mice is observed in single-
and group-housed animals during light and dark phases of the
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diurnal cycle and appears in two types: (i) LAB-Intermediate
(LAB-I) mice are animals with non-habituating locomotion
slightly exceeding the ambient activity in NAB and HAB
mice; and (ii) LAB-Strong (LAB-S) mice showing 3-fold higher
locomotor activity (Yen et al., 2013). All experiments presented
here were performed in LAB-I mice, which represent the
majority of the offspring (>60%) and most closely fulfill the
criteria for an animal model of ADHD (Yen et al., 2013).
For the sake of clarity, the abbreviation ‘‘LAB’’ is used instead
of ‘‘LAB-I’’ throughout the manuscript. All mice were single-
housed under standard laboratory conditions with reversed
12/12 h light/dark cycle (light on at 9 pm), temperature 23 ±
1◦C, food and water ad libitum approximately 2 weeks before
experiments started. We performed basal locomotor tests with
all mice in order to exclude LAB-strong animals, followed by
verification of the calming response of amphetamine at an age
of 2.0--2.5 months. To meet the 3R’s rule of animal welfare we
repeatedly (3--4 times) tested mice that was possible due to a
stability of endophenotypes (Yen et al., 2013). Given the inter-
trial intervals (5--10 days) animals were available for subsequent
tests at an age of 3--6 months. Nonetheless, to exclude any
confounding effect of the repeated exposure animal to the OF
and/or a carryover effect of injections and previous treatments,
we always analyzed the basal activity measured before any
treatment (first 20 min of the OF test). Experiments with
between-line comparisons were performed at the same time.
Number of animals in the experimental groups varied from 4--13.
The exact sample size is indicated in the figures/figure legends.
All experiments were carried out according to the European
Community Council Directive 2010/63/EEC, and efforts were
made to minimize animal suffering. All experimental procedures
were approved by the local government of Upper Bavaria
(55.2.1.54-2532-188-12).
Drugs and Doses
d-Amphetamine hemisulfate (Amph), methylphenidate
hydrochloride, lithium chloride (LiCl), TDZD-8, and dimethyl
sulfoxide (DMSO) were from Sigma-Aldrich (USA). Haloperidol
stock solution was from Ratiopharm GmbH (Germany).
Amphetamine, methylphenidate, LiCl powders and haloperidol
stock solution were dissolved in saline. TDZD-8 stock solution
was prepared in 100% DMSO and then dissolved in saline to
achieve a final DMSO concentration of 0.5% v/v. All working
solutions were prepared freshly before each experiment.
Amphetamine (0.5, 1, and 2 mg/kg) and methylphenidate (3, 10,
and 30 mg/kg) were injected in doses which did not induce
toxic effect and result in stereotypic behavior. Haloperidol was
injected at the dose of 1 mg/kg for reproducing the catalepsy
(Boulay et al., 2000; McOmish et al., 2012). The LiCl dose
(100 mg/kg) was chosen to trade-off the specific antimanic and
gustatory/digestive tract aversive effects of this drug (Gould
et al., 2007). The TDZD-8 dose (20 mg/kg) was selected on
the basis of our preliminary experiments (not shown) and the
previous report (Beaulieu et al., 2004). All drugs were injected
intraperitoneally (i.p.) in the volume of 100 µl/10 g of body
weight. The doses for amphetamine (1.8 ng/0.5 µl/side) and
TDZD-8 (1.1 ng/0.5 µl/side) microinjections were chosen on the
basis of the previous reports (Prasad et al., 1999; Chen et al., 2004;
Ramirez et al., 2010). Control groups received the respective
vehicle injection/microinjection, saline or 0.5% DMSO.
Behavioral Tests
All behavioral experiments were performed during the active
phase of the diurnal cycle between 10 am and 6 pm.
Locomotor activity was assessed in the OF test by
measurement of the distance traveled with the automatic
TruScan Photo Beam Activity system (Coulbourn Instruments,
Whitehall, PA, USA) as described previously (Yen et al., 2013).
Basal activity was measured within 20 min prior to systemic drug
administration. After an i.p. injection (which lasted less a 1 min)
mice were returned to the test arena and recording was continued
for 1 or 2 h. In the case of mPFC and striatum local treatment,
recording started 2--3 min after microinjections and lasted for
1 h. Data were analyzed in 5 min bins; in some cases, we report
mean data corresponding to either 20 min intervals or the entire
observation period.
Stereotypic behavior assessment was done in accordance
to Havemann et al. (1986) rating scale: 0 (no stereotypies);
1 (discontinuous sniffing); 2(continuous sniffing); 3 (disconti-
nuous licking); 4 (continuous licking); 5 (discontinuous
gnawing); 6 (continuous gnawing).
Catalepsy test was performed as described (Sanberg, 1980).
Modification was done by adjusting the horizontal bar in a way
that the mouse’s forepaws were paced 3 cm above the floor level.
The latency of the mouse to descend from the inconvenient
postures was recorded by a trained observer; immobility for more
than 5 min was scored as 300 s.
Brain Microdialysis
Surgery, probe implantation, and microdialysis were done as
described before (Anderzhanova et al., 2013).Microdialysis guide
cannulas (Microbiotech/se AB, Sweden) were implanted into
the right mPFC (coordinates: AP 2.20 mm, ML 0.35 mm, and
DV−1.50 mm) or right striatum (coordinates: AP 0.50 mm, ML
2.00 mm, and DV −2.25 mm) in accordance with Paxinos and
Franklin Mouse Brain Atlas (Paxinos and Franklin, 2001) under
isoflurane (Abbot, India) Metacam® (Boehringer Ingelheim
GmbH, Germany) anesthesia. Recovery lasted for 1 week and
included Metacam® supplementation 0.25 mg/100 ml with
drinking water. Microdialysis probes (o.d. 0.2 mm, cuprophane
membrane 2 mm of length, MAB 4.15.2.Cu, Microbiotech/se AB,
Sweden) were inserted under slight isoflurane anesthesia and
then continuously perfused with sterile artificial cerebrospinal
fluid (concentrations, in mM: NaCl 145, KCl 2.7, CaCl2 1.2,
MgCl2 1.0, Na2HPO4 2.0, pH = 7.4). Microdialysis fractions
(20 min) were collected during experimental days 1, 2 and 3 at
a flow rate of 1.0 µl/min. In order to minimize the number of
animals, microdialysis experiments lasted for three consecutive
days during which different pharmacological treatments were
given in the same order for each animal. Amphetamine and
methylphenidate were injected on the first day 5 h apart
allowing recovery of both behavior and catecholamine levels.
Amphetamine andMK-801 or saline were injected on the second
day, haloperidol on the third day.
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Monoamine assays. Dopamine, norepinephrine, and
homovanillic acid (HVA) contents were determined by reverse-
phase HPLC with electrochemical detection (UltiMate3000
CoulochemIII, ThermoFischer, USA). All reagents used for
the mobile phase were of analytical grade (Carl Roth GmbH
or MERCK KGaA, Germany). Monoamines were separated
on an analytical column (C18, 150 mm × 3 mm, 3 µm,
YMC Triart, YMC Europe GmbH, Germany) at a flow rate of
0.4 ml/min. The potentials of the working electrodes were set at
−150 mV, +220 mV, the guard cell potential was set at +350 mV.
Monoamine concentrations were calculated by external standard
curve calibration using the peak area for quantification. The
detection limits for norepinephrine and dopamine were 0.032
and 0.040 nM, respectively; therefore few data sets were excluded
from analysis.
Basal levels were not corrected by an in vitro recovery
examination. The values were stable across 3 days of
measurement both in the mPFC and in the striatum. One-
way ANOVA did not reveal any differences between the day
groups in HAB or LAB mice (Fs< 0.74, ps> 0.40).
Drug Microinjections
Custom-designed stainless steel injection cannulas (23G)
were bilaterally implanted into the mPFC (AP 1.90 mm,
ML ± 0.40 mm, and DV −2.00 mm; Figure 5A) and the
striatum (AP 0.50 mm, ML ± 2.00 mm, and DV −3.00 mm;
Figure 5D) (Paxinos and Franklin, 2001). Recovery took
1--2 weeks. Injections were done directly before OF tests under
slight isoflurane anesthesia. Injections were performed by
means of a cannula (0.3 mm o.d.), which was connected to a
microliter syringe (65RNR 10.0 µL SYR, Hamilton Bonaduz AG,
Switzerland) via calibrated tubing. Once inserted, the injection
cannula protruded from the guide cannula1 mm, thus reaching
the prelimbic mPFC or the dorso-lateral striatum. Different
injection sets were used for drug and vehicle.
Tissue Isolation from Frozen Brains
Animals were i.p. injected with saline, amphetamine (1
mg/kg), and MK-801 (0.3 mg/kg) in accordance with the
corresponding protocols and examined in the OF test. Sixty
minutes after the injections, animals were lightly anesthetized
and decapitated, brains removed, immediately frozen on dry
ice, and kept at −80◦C. Biopsy punches of the mPFC and
the striatum were done with pre-chilled stainless steel sample
corers (diameters of 0.8 mm and 1.0 mm for the mPFC and
striatum, respectively) (Fine Science Tools GmbH, Germany)
from coronal sections of the brains at −20◦C (Tzigaret et al.,
1993). The withdrawn regions are schematically depicted in
Figures 4D,E. Specimens from the right and left hemispheres
were pooled together and stored at −80◦C prior to western blot
analysis.
Western Blot Analysis
Western blot analysis was performed as described previously
(Zschocke et al., 2011). Protein extracts were obtained by
lysing the brain punches in 62.5 mM Tris, 2% SDS and
10% sucrose, completed with protease (Sigma, P2714) and
phosphatase (Roche, 04906837001) inhibitor cocktail. Samples
were sonicated and heated at 95◦C for 10 min. SDS-PAGE
was carried out to separate proteins. Proteins were electro-
transferred onto nitrocellulose membranes. Blots were placed
in Tris-buffered saline (TBS), supplemented with 0.05%
Tween (Sigma, P2287, USA) and 5% non-fat milk for 1 h
at room temperature and then incubated with primary
antibody (diluted in TBS/0.05% Tween) overnight at 4◦C.
The following primary antibodies were used: GSK3β (1:1000,
Cell Signaling, #9315), phospho-Ser9-GSK3β (1:1000, Cell
Signaling, #9323), Actin (1:5000, Santa Cruz Biotechnologies,
sc-1616), HSC70 (1:5000, Santa Cruz Biotechnologies, sc-7298).
Subsequently, blots were washed and probed with the respective
horseradish peroxidase- or fluorophore-conjugated secondary
antibody for 1 h at room temperature. The immuno-reactive
bands were visualized either by using ECL detection reagent
(Millipore, Billerica, MA, USA, WBKL0500) or directly by
excitation of the respective fluorophore. Determination
of the band intensities was performed with ChemiDoc
MP (BioRad, CA, USA). The Western blot protocols were
adapted to process small quantities of biological material
which could be obtained upon brain structure punching.
Low content of proteins and respective adjustments of the
Western blot image reader sensitivity in particular cases
influenced the image quality. Nonetheless, the sample bits
were enough for reliable quantification. Comparison for
optical density revealed a difference between the experimental
groups.
The phosphorylation index was used as an indicator of kinase
activity. Drug and line effects were evaluated in comparison to
either saline- (Figures 4G,I,K) and amphetamine- (Figure 7D)
treated groups or NAB mice (Figure 4F). Drug-induced dose-
dependent changes were evaluated after normalization to
vehicle-treated specimens.
Mass Spectrometry-Based GSK3β Kinase Assay
Determination of GSK3β kinase activity in the presence of
TDZD-8, LiCl, methylphenidate, amphetamine, or vehicle was
done as in Bowley et al. (2005) with slight modifications. The
kinase reaction buffer was supplemented with 1 mM ATP,
0.2 mM DTT, protease inhibitor (Sigma, P2714), phosphatase
inhibitor (Roche, 04906837001), and 45 ng of recombinant
GSK3β (BPS Bioscience, CA, USA). A MALDI-ToF mass
spectrometer (Ultraflex I, Bruker Daltronics) was used for
analysis. The ratio between concentrations of phosphorylated
and total substrate 2B-Sp was used as an index of kinase
activity.
Histology
Cryo-sections of 25 µm obtained from target or punched
brain regions were stained with cresyl violet (Carl Roth
GmbH, Germany) and verified under a microscope using the
Paxinos and Franklin mouse atlas (Paxinos and Franklin, 2001).
Schematic representations of the targeted regions are shown
in Figures 2A,D, 4D,E, 5A,D. When probe/cannula placement
was found to be out of the targeting area, the respective
samples/animals were discarded before analysis.
Frontiers in Behavioral Neuroscience | www.frontiersin.org 4 March 2015 | Volume 9 | Article 67
Yen et al. Paradoxical calming effect of amphetamine and GSK3β
Experiments’ Outline
Different cohorts of LAB, NAB and HAB mice were used in each
experiment. The sizes of groups are indicated in the Figures.
Experiment 1.1. Comparison of the mean basal locomotor
activities (20 min OF test in drug naïve animals) between LAB,
NAB, and HABmice. Experiment 1.2. Between line (HAB, NAB
and LAB mice) comparison of amphetamine (0.5, 1.0, and 2.0
mg/kg, i.p) and methylphenidate (3, 10, 30 mg/kg, i.p.) dose-
response effects on the gain or loss in themean locomotor activity
within 60 min after drug administration (OF test).
Experiment 2.1. Evaluation of acute neurochemical
changes in the mPFC of LAB and HAB mice evoked by
systemic administration of amphetamine (1 mg/kg, i.p.; this
dose is used in the next experiments) and methylphenidate
(10 mg/kg) (microdialysis). Experiment 2.2. Evaluation of
acute neurochemical changes in the striatum of LAB and HAB
mice evoked by systemic administration of amphetamine and
methylphenidate (microdialysis). Experiment 2.3. Examination
of the locomotor activity dynamics within 60--120 min after
systemic amphetamine andmethylphenidate treatment (OF test).
Experiment 3.1. Comparison of haloperidol (1 mg/kg, i.p.)
effects on the loss in the mean locomotor activity within
60 min after drug administration in LAB and HAB mice
(OF test). Experiment 3.2. Examination of cataleptogenic
activities of amphetamine and haloperidol in LAB mice (descent
latency measurement at 60 min after drug administration).
Experiment 3.3. Evaluation of acute neurochemical changes in
the mPFC after haloperidol treatment in LAB and HAB mice
(microdialysis).
Experiment 4.1. Comparison of the locomotor activity within
60 min after GSK3β inhibitors (TDZD-8, 20 mg/kg and LiCl, 100
mg/kg, i.p; these doses are used in the next experiments) and
amphetamine administration in LABmice (OF test). Experiment
4.2. Comparison of TDZD-8, LiCl, and amphetamine effects on
the loss or gain in the mean locomotor activity within 60 min
after drug administration in LAB, NAB, and HABmice (OF test).
Experiment 5. Comparison of the amphetamine,
methylphenidate, LiCl, and TDZD-8 GSK3β inhibitory activity
in vitro.
Experiment 6. Examination of systemic amphetamine
administration effects on GSK3β phosphorylation levels
observed at 60 min after drug i.p. injection in the mPFC and in
the striatum of LAB, NAB, and HAB mice (Western blot).
Experiment 7. Comparison of changes in locomotor activity
within 60 min after amphetamine and TDZD-8 bilateral
microinjections into the mPFC and into the striatum in LAB
mice (OF test).
Experiment 8.1. Evaluation of the locomotor activity
dynamics within 60 min after MK-801 (0.3 mg/kg, i.p.; this dose
is used in the next experiments) treatment in LAB and HABmice
(OF test). Experiment 8.2. Examination of MK-801 effects of the
amphetamine-induced dopamine release in the mPFC of LAB
and HAB mice (microdialysis).
Experiment 9.1. Comparison of administration time-
dependent (pre-, co- and post-treatment) effects MK-801 on
the amphetamine-mediated locomotion mitigation in LAB
mice (OF test). Experiment 9.2. Evaluation of the MK-801
and amphetamine interaction in regulation of GSK3β
phosphorylation in the mPFC of LAB mice (Western blot).
Experiment 9.3. Examination of MK-801 pre-treatment effects
on the LiCl-evoked locomotion mitigation in LAB mice (OF
test). Experiment 9.4. Examination of MK-801 co-treatment
effects on TDZD-8-evoked locomotion mitigation in LAB mice
(OF test).
Data and Statistical Analysis
Considering the basal difference in the absolute values
of locomotor activities between LAB and HAB mice
(Figures 1A, 2F,F,G,G), the OF data were normalized to
better visualize relative changes in the traveled distance after
drug administration. The applied algorithm (Hinkelmann
et al., 2010) employs a comparison of running values (xi) and
measurement of the last 5 min of the pretreatment period
(x4). Relative changes were calculated in accordance with the
equation: xi(%) = 200·(x2i )/(x2i + x24). Gains and losses in the
distance traveled were obtained by subtraction of normalized
values from 100%. Such a way of data normalization ensures
that relative changes in locomotion will be displayed in the
ranges of 0%+100% (gain) and 0%−100% (loss), thus avoiding
any bias towards increase locomotion on expenses of decreased
locomotion. Microdialysis data were expressed as a percentage
of absolute dopamine and norepinephrine basal values (basal
values were the means of three consecutive samples) or as
absolute concentrations in the microdialysates (for basal levels
only). All data are expressed as mean ± S.E.M. The sample sizes
were chosen on the basis of our previous experience with the
procedures used, and they are adequate to detect meaningful
differences between conditions. Statistical analyses were
performed with Statistica, version 5.0 (StatSoft Inc., Tusla, OK,
USA). Data were analyzed with the Kolmogorov-Smirnov for
distribution and met the assumptions of the test with regard to
normality, skew and homogeneity of variance. Mice of each line
were randomly assigned to the treatments for between-groups
comparison in microdialysis experiments. Counterbalanced
assignment of treatment order for within-subject design was
used in behavioral experiments. Experimenters were blind to
either the subline or the treatment assignments. Statistics were
two-tailed t-test, one-way ANOVA, two-way ANOVA (the
factorial design included the time and line or treatment factors
for analysis of dynamic locomotor activity and microdialysis
data; structure and treatment factors for analysis for molecular
data; in any other cases the design is specified particularly in
the respective part of Results) and followed by Neuman-Keuls’s
or Dunnett’s or Bonferoni’s post hoc tests, if appropriate. All
differences were considered significant at p< 0.05.
Results
The Calming Effect of Amphetamine is not
Mirrored by Changes in Monoamine Release
To confirm the hyperactive phenotype of LAB mice (Yen
et al., 2013), we exposed LAB, NAB and HAB mice to an
OF for 20 min (Experiment 1.1). LAB mice showed the
elevated mean basal activity during 20 min exposure to the OF
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FIGURE 1 | Amphetamine and methylphenidate action on locomotor
activity (A). LAB mice are strictly different from NAB and HAB mice in their
mean basal locomotor activity observed within 20 min in the OF
(***p < 0.001). (B). Dose-dependent effect of amphetamine on locomotor
activity in OF test. Here and in the next graph, data represent relative changes
(gain or loss) in the mean total distance traveled within 60 min after drug
administration in comparison to basal activities (last 5 min of pre-treatment
20 min period). Asterisks show the result of the Dunnett’s post hoc test
comparing the effect of different doses with saline effect. (C). Dose-dependent
effect of methylphenidate on locomotor activity in OF test. The two-tailed
Student’s test in the cases of HAB and NAB mice revealed a difference
(depicted with hash marks, ###p < 0.001) between changes in locomotor
activity after saline and drug treatment. (Asterisks show the result of the
Dunnett’s post hoc test comparing the effect of different doses with saline
effect in LAB mice. *p < 0.05, **p < 0.01, ***p < 0.001; n.e. not examined;
numbers on the graph panels represent group size.
(791.0 ± 33.12 cm) compared to NAB (484.0 ± 13.66 cm) and
HAB mice (438.7 ± 15.21 cm), which were indistinguishable
from each other (one-way ANOVA with Bonferroni’s post hoc
test; F(2) = 72.72, p< 0.0001; Figure 1A).
LAB mice differed from NAB and HAB mice in their profile
of changes in the mean total distance traveled after amphetamine
and methylphenidate administration (Experiment 1.2). Amphe-
tamine exerted a calming activity in LAB mice and increased
locomotion in NAB and HAB mice in a range of doses
(0.5--2.0 mg/kg, i.p.). Two-way ANOVA (line, dose) exploring
amphetamine effects showed significance for all factors (line:
F(2,130) = 61.97, p < 0.0001; dose: F(3,130) = 12.03, p < 0.0001;
line x dose: F(6,130) = 19.79, p < 0.0001). The subsequent
one-way ANOVAs performed separately per line points to
significance of amphetamine dose effect in each line (LAB:
F(3) = 45.71, p < 0.001; NAB: F(3) = 8.87, p = 0.001; HAB:
F(3) = 15.46, p < 0.001; Figure 1B), however expressed in
a different directions. Methylphenidate showed its stimulatory
activity in all lines injected with 3 doses (3.0, 10.0, 30.0 mg/kg).
The one-way ANOVA for LAB mice points to significant dose
effect (F(3) = 7.20, p = 0.0013). The two-tailed Student’s test in
the cases of HAB and NAB mice revealed a difference between
changes in locomotor activity after saline and drug treatment
(HAB mice, t(16) = 18.05, p < 0.007, NAB mice t(20) = 13.72,
p < 0.0001; Figure 1C). The stereotypia scores were always
of zero levels. In no case did we detect even initial signs
of amphetamine-specific (discontinuous sniffing) stereotypic
behavior which might have explained the decrease in locomotor
activity found in LAB mice.
On the basis of these results and considering the monoamine
releasing potency of amphetamine and methylphenidate
reported in the literature, we selected 1 mg/kg for amphetamine
and 10 mg/kg for methylphenidate for the subsequent
neurochemical studies. In these studies, we asked whether
the differences in behavioral effects of amphetamine vs.
methylphenidate in LAB mice (i.e., reduction vs. increase in
locomotor activity) were reflected by similar differences in
dopamine and norepinephrine levels in the mPFC and/or the
striatum. This was done in comparison to HAB mice, which
were most responsive to any of the drugs in terms of increased
locomotion. Microdialysis was performed in the mPFC and in
the striatum in independent groups of mice.
In the first cohort of animals (Experiment 2.1) microdialysis
probes targeted the mPFC including the cingulate cortex (Cg1),
the prelimbic cortex (PrL) and the infralimbic cortex (IL;
Figure 2A). Mean basal catecholamine levels were evaluated
in the entire pool of basal samples in drug-naive animals
(day 1) (HAB, n = 5; LAB, n = 5). Comparison of the absolute
extracellular dopamine levels measured in the mPFC failed
to reveal any line differences for both the basal dopamine
(t(21) = 0.61, p = 0.556; Figure 2A) and the norepinephrine
(t(21) = 1.22, p = 0.236; Figure 2A) content.
As revealed by two-way ANOVAs (line, time), both
amphetamine (1 mg/kg, i.p.) (time: F(8,66) = 3.04, p = 0.007;
Figure 2B) and methylphenidate (10 mg/kg, i.p.) (time:
F(8,80) = 2.51, p = 0.019; Figure 2C) caused a pronounced increase
in the relative dopamine release in the mPFC irrespective of the
mouse line (time: Fs> 2.59, p< 0.019 line: Fs< 0.10, p> 0.752;
time x line: Fs < 0.39, p > 0.916). Results were essentially the
same for norepinephrine (time: Fs> 9.08, p< 0.001; time x line:
Fs < 0.64, p > 0.744; Figures 2B,C), except for a significantly
higher release inHABmice followingmethylphenidate treatment
(line: F(1,77) = 5.43, p = 0.023). In each case, catecholamine levels
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FIGURE 2 | Amphetamine and methylphenidate action on dopamine and
norepinephrine release (A1, D1). The schematic diagrams show placement
of microdialysis probes in subsequent coronal sections of the mPFC and
striatum. The computer-based atlas by Paxinos and Franklin (2001) was used to
mark probe locations; numbers refer to distances from the bregma, mm.
(A2,3,D2). Basal values of dopamine and norepinephrine in the mPFC and
dopamine in the striatum of LAB and HAB mice. *p < 0.01; “n/N” represent the
sample size/number of animals under evaluation. Amphetamine (1 mg/kg, i.p.)
and methylphenidate (10 mg/kg, i.p.) evoke comparable dopamine and
norepinephrine release in the mPFC (B1,2,C1,2) and striatum (E1,2) of both
LAB (circles) and HAB (triangles) mice. Amphetamine (1 mg/kg, i.p.) decreases
hyperactivity in LAB mice (circles in contrast to the stimulatory effect in HAB
mice (triangles) (F1,2). Methylphenidate (10 mg/kg, i.p.) stimulates locomotion
in both lines (G1,2). The dashed lines define the moment of drug administration.
peaked within the first 20 min after treatment, followed by a
return towards basal levels within 2 h.
In the second cohort of mice (Experiment 2.2) microdialysis
probes were implanted into the dorso-lateral part of the striatum
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(Figure 2D). Basal levels of dopamine were lower in LAB (n = 8)
mice in comparison to HAB (n = 5) mice (t(37) = 2.92, p = 0.006;
Figure 2D). As shown by two-way ANOVAs, both amphetamine
(1 mg/kg, i.p.) (time: F(8,110) = 30.38, p < 0.001; Figure 2E)
and methylphenidate (10 mg/kg, i.p.) (time: F(8,80) = 43.21,
p< 0.0001; Figure 2E) caused a significant increase in dopamine
release, which was the same in HAB and LAB mice (line:
Fs < 0.263, p > 0.668; time x line: Fs < 1.11, p > 0.365).
Norepinephrine levels were below the detection limit. Again,
dopamine levels peaked within 20 min after injection and
returned to baseline within 2 h.
In a separate cohort of LAB and HAB mice we monitored
changes in the distance traveled within 60--120 min after
amphetamine (1 mg/kg, i.p.) and methylphenidate (10 mg/kg,
i.p.) administrations (Experiment 2.3). It is of note that the
transient increase in locomotor activity upon amphetamine
(two-way ANOVA, treatment: F(1,120) = 9.17, p = 0.0066;
Figure 2F) and methylphenidate (two-way ANOVA, treatment:
F(1,33) = 47.11, p < 0.0001; Figure 2G) treatment in HAB and
methylphenidate treatment in LAB mice (two-way ANOVA:
treatment: F(1,45) = 40.06, p = 0.0008; Figure 2G), with return
towards basal levels within 1 h, closely resembled the release
patterns of dopamine and norepinephrine. The calming effects
of amphetamine in LAB mice (two-way ANOVA: treatment:
F(1,66) = 58.75, p < 0.0001; Figure 2F), in contrast, outlasted by
far the neurochemical changes.
Collectively, the microdialysis experiments did not reveal
any differences in dopamine or norepinephrine release upon
treatment with amphetamine between LAB and HAB mice,
which would explain the opposite behavioral effects. Moreover,
amphetamine and methylphenidate showed comparable effects
on dopamine and norepinephrine release in LAB mice despite
their different effects on locomotor activity.
Dopamine D2 Receptor Function is not Impaired
in LAB Mice
There is evidence for a critical involvement of dopamine
D2 receptor in amphetamine behavioral effects (Seeman and
Madras, 1998; Beaulieu et al., 2004, 2005). Therefore, we
investigated whether dopamine D2 receptor signaling was
altered in LAB mice under basal conditions. To this end, we
examined behavioral (locomotor activity and catalepsy) and
neurochemical changes induced by systemic administration
of haloperidol. Haloperidol (1 mg/kg, i.p.) equally decreased
locomotor activity in the OF test in both LAB and HAB
mice (Experiment 3.1) (two-way ANOVA, line: F(1,27) = 1.75,
p = 0.197; treatment: F(1,27) = 63.48, p < 0.0001; line x
treatment: F(1,27) = 2.77, p = 0.109; Figure 3A); for details
concerning the dynamics of locomotor activity changes see Yen
et al. (2013). Haloperidol also caused a significant increase in
catalepsy in LAB mice (Experiment 3.2). The descent latency
from an involuntary posture increased 60 min after haloperidol
administration, whereas amphetamine treatment (1 mg/kg,
i.p.) had no effects compared to vehicle (one-way ANOVA:
F(2) = 10.84, p = 0.0004; Figure 3B). This proves the specificity
of amphetamine-induced decrease in locomotor activity in these
animals.
We also examined the efficacy of dopamine D2 receptors
to affect dopamine release on the local level (presynaptic
autoreceptor-mediated release regulation) (Experiment 3.3). As
revealed by two-way ANOVA, haloperidol elicited an increase
in dopamine (time: F(11,93) = 2.32, p = 0.017; Figure 3C) and
HVA (time: F(11,80) = 28.49, p < 0.001; Figure 3D) levels in the
mPFC, with no differences between the two lines (line: Fs< 2.41,
p> 0.125, time x line: Fs< 1.46, p> 0.337).
Taken together, these results demonstrate intact functions
of dopamine D2 receptors, both pre- and postsynaptic, in LAB
mice. Moreover, the calming effect of amphetamine does not
result from any cataleptic-like effect.
GSK3β Inhibitors Attenuate Hyperlocomotion in
LAB Mice
We showed before, that LiCl decreased the hyperactivity in
LAB mice (Yen et al., 2013). Pharmacological activity of lithium
is mediated by both direct and indirect inhibition of GSK3β
(Beaulieu et al., 2009). Therefore, we compared the effects of
amphetamine (1 mg/kg, i.p.), LiCl (100 mg/kg, i.p.), and the
selective GSK3β inhibitor TDZD-8 (20 mg/kg, i.p.) on the
locomotor activity in LAB, NAB, and HABmice (Experiment 4.1
and 4.2). In LAB mice, TDZD-8 did not affect the locomotion in
the OF test at a dose of 10 mg/kg, i.p. (data not shown). However,
a dose of 20 mg/kg, i.p., sufficed to decrease hyperactivity.
Notably, TDZD-8 elicited changes in locomotor activity which
were qualitatively and quantitatively similar to the effects of
amphetamine and LiCl: a rapid and lasting decline in activity
(two-way ANOVA: treatment: F(2,275) = 0.48, p = 0.625; time:
F(15,275) = 82.81, p < 0.0001; time x treatment: F(15,275) = 2.47,
p < 0.0001; Figure 4A). The increase in the selectivity of
the GSK3β inhibitors (LiCl vs. TDZD-8) went along with a
loss in line specificity in their calming action: Though LiCl
decreased locomotor activity in NAB, but not in HAB mice,
TDZD-8 was effective in all three lines. Two-way ANOVA
(line x treatment) showed significance for each factor and
their interaction (treatment: F(1,61) = 21.685, p < 0.0001; line:
F(1,61) = 17.65, p < 0.0001; treatment x line: F(1,61) = 7.44,
p< 0.0001) (Figure 4B).
Although the acute effects of amphetamine and TDZD-8 were
comparable in LAB mice, we observed a critical difference in
delayed toxic impact of the two drugs: 2--3 days (but not 24 h)
after treatment with TDZD-8 the animals showed a mortality
rate of 30%. This may be related to a strong peripheral metabolic
effect of the selective GSK3β inhibitor. In contrast, we failed
to observe any fatal consequences for amphetamine treatment
despite the huge number of treated mice (more than 100 over
3 years).
Similar profiles of hyperactivity mitigation after GSK3β
inhibitor (TDZD-8, LiCl) and amphetamine administration in
LAB mice strongly suggest that these compounds share a
common molecular mechanism of action.
Amphetamine Selectively Increases GSK3β
Phosphorylation in the mPFC of LAB Mice
The similarities in the behavioral consequences of amphetamine
and GSK3β inhibitors prompted us to investigate whether
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FIGURE 3 | Behavioral and neurochemical effects of haloperidol (A).
Haloperidol (1 mg/kg, i.p.) decreases the total distance traveled by both LAB
and HAB mice; the corresponding dynamical data are presented in Yen et al.
(2013). Relative gains or losses in the mean distance traveled within 60 min after
treatment was obtained in comparison to basal activities (last 5 min of
pre-treatment 20 min period). A subtle difference between saline-treated LAB
and HAB mice reflecting the already reported difference in the short-term
habituation rate in these animals (Yen et al., 2013). However, the
locomotion-suppressive effects of haloperidol (1 mg/kg, i.p.) were prominent
both in LAB and HAB mice and did not differ between lines.***p < 0.001,
*p < 0.05, n.s. non significant (Newman-Keuls’s post hoc comparison).
(B). Mitigation of locomotor activity by haloperidol (1 mg/kg, i.p.) in LAB mice is
mediated by its characteristic neuroleptic activity (development of a cataleptic
state) which can be discriminated from the calming action of amphetamine
(1 mg/kg, i.p.). **p < 0.01, ***p < 0.001 (Neumann-Keuls’s post hoc
comparison). (C,D). Haloperidol (1 mg/kg, i.p.) increases dopamine release in
the mPFC and evokes equal accumulation of HVA in both LAB (circles) and HAB
(triangles) mice. The dashed line defines the moment of drug administration.
amphetamine directly interferes with GSK3β. To address this
question, we examined the GSK3β inhibitory activity for
amphetamine and methylphenidate in vitro (Experiment 5).
Amphetamine and methylphenidate did not decrease the activity
of purified GSK3β in vitro. In contrast, in this preparation,
lithium effectively inhibited GSK3β, as well as did TDZD-8
(Figure 4C).
We next looked for changes in GSK3β phosphorylation
in vivo, assuming an indirect interaction (Experiment 6). To this
end, we treated HAB, NAB and LAB mice with amphetamine
(1 mg/kg, i.p.) and measured the levels of phospho-Ser9-GSK3β
(pGSK3β) in the mPFC (Figure 4D) and in the striatum
(Figure 4E) 60 min later. Between-line (LAB, NAB, and HAB
mice) comparison (two-way ANOVA, line, structure) revealed
no difference in the phosphorylation for GSK3β, neither in
the mPFC and in the striatum of vehicle-treated animals (line:
F(2,59) = 3.69, p = 0.307; structure: F(1,59) = 4.21, p = 0.102;
interaction: F(1,59) = 2.21, p = 0.489; Figure 4F) nor in total
GSK3β levels (not shown). This speaks against a significant
role of GSK3β in basal differences in locomotor activity.
Following amphetamine treatment of LAB mice, however,
GSK3β phosphorylation was significantly increased in both
the mPFC and striatum. Three-way ANOVA (line x structure
x treatment) showed significance of each factor and their
interactions (Fs > 6.62, ps < 0.0011). Respectively, the two-
way ANOVA confirmed the effect of amphetamine in each
line group separately (treatment: F(1,33) = 47.58, p < 0.0001;
structure: F(1,33) = 0.57, p = 0.54; treatment x structure:
F(1,33) = 0.57, p = 0.54; Figures 4G,H). Amphetamine also
increased the phosphorylation of GSK3β in NAB mice. This,
however, was only the case for the striatum, but not for themPFC
(treatment: F(1,26) = 21.44, p = 0.0001; structure: F(1,26) = 24.22,
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FIGURE 4 | Amphetamine treatment results in GSK3β inhibition (A).
Amphetamine (1 mg/kg, i.p., circles), LiCl (100 mg/kg, i.p., squares), and
TDZD-8 (20 mg/kg, i.p., diamonds) mitigate the locomotor activity in LAB
mice with the same dynamics. The dashed line defines the moment of drug
injection; n.s. non significant. (B). Within-line comparison of amphetamine
(1 mg/kg, i.p.), LiCl (100 mg/kg, i.p.), TDZD-8 (20 mg/kg, i.p.), and saline
effects on the locomotor activity in LAB, NAB, and HAB mice illustrates the
similar ability of all drugs to decrease the traveled distance in LAB mice.
Relative gains or losses in the mean distance traveled within 60 min after
treatment was obtained in comparison to basal activities (last 5 min of
pre-treatment 20 min period). Analysis confirms the selectivity of
amphetamine action in LAB mice and points to a lack in line specify of LiCl
and, in particular, TDZD-8 to inhibit locomotion. *p < 0.05, **p < 0.01,
***p < 0.001, within line comparison, Bonferroni’s post hoc test. Numbers on
the bars represent the group size. The same order of treatments was applied
for each line. (C). Lithium chloride and TDZD-8 show a direct inhibition of
recombinant GSK3β in vitro effectively reducing (p < 0.001) its activity in a
dose-dependent manner. Neither amphetamine nor methylphenidate inhibit
recombinant GSK3β in vitro. (D,E). Schematic representation of punched
areas in the mPFC and the striatum. The computer-based atlas by Paxinos
and Franklin (2001) was used to mark probe locations; numbers refer to
distances from the bregma, mm. (F). Western blot kinase analysis for the
mPFC and the striatum of drug naïve mice shows no difference between LAB
(n = 8/11), NAB (n = 11/12) and HAB mice (n = 11/12) in pGSK3β levels.
(G,I,K). Changes in the pGSK3β levels in the mPFC and the striatum of LAB,
NAB, and HAB mice 60 min after amphetamine (1 mg/kg, i.p.) and saline
treatment and coinciding with OF exposure. **p < 0.01, ***p < 0.001 vs.
saline (H,J,L). Representative Western blots for analysis of GSK3β, pGSK3β
protein level. Bands include samples both from amphetamine and
saline-treated animals. Numbers on the graph panels represent group size.
p < 0.0001; treatment x structure: F(1,26) = 24.22, p < 0.0001;
Figures 4I,J). In HAB mice, we did not observe any changes
in GSK3β phosphorylation, irrespective of the brain structure
(treatment: F(1,36) = 4.00, p = 0.217; structure: F(1,36) = 2.21,
p = 0.357; treatment x structure: F(1,36) = 2.21, p = 0.357;
Figures 4K,L).
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FIGURE 5 | Local amphetamine and TDZD-8 treatment (A,D).
Schematic representation of the drug infusion loci. The rectangles
correspond to tracks of the injection cannula tip (1 mm) in the mPFC and
the striatum. Results for right and left hemisphere examinations are pooled
together. The computer-based atlas by Paxinos and Franklin (2001) was
used to mark probe locations; numbers refer to distances from the bregma,
mm. Amphetamine (1.8 ng/side, B) and TDZD-8 (1.1 ng/side, C) transiently
counteract the hyperlocomotor activity in LAB mice when injected in the
mPFC. Amphetamine (1.8 ng/side, E) rather stimulates locomotion, when
injected in the striatum, whereas TDZD-8 (1.1 ng/side, F) does not exert any
action. The dashed lines mark the moment of drug administration (2--3 min
before the animal is placed into the OF test box). Open circles correspond
to saline/vehicle treatment; filled circles correspond to drug treatment.
*p < 0.05, **p < 0.01.
In summary, amphetamine treatment caused line-dependent
and structure-specific changes in GSK3β phosphorylation,
whereby LAB mice displayed a selective increase in GSK3β
phosphorylation in the mPFC.
Selective Inhibition of GSK3β and Amphetamine
Activity in the mPFC, but not in the Striatum,
Mitigates Hyperlocomotion in LAB Mice
The Western blot data suggest a scenario according to
which amphetamine mediates hypolocomotion via increased
phosphorylation (i.e., inhibition) of GSK3β at the PFC rather
than the striatal level. We verified this assumption by local
application of amphetamine or TDZD-8 in the mPFC or
striatum of LAB mice (Experiment 7) (Figures 5A,D). Bilateral
administration of amphetamine (1.8 ng/0.5 ul/side) in the
mPFC indeed decreased locomotor activity compared to vehicle
immediately after drug infusion (two-way ANOVA: treatment:
F(1,165) = 2.00, p = 0.177; time: F(11,165) = 8.66, p < 0.0001;
treatment x time: F(11,165) = 2.27, p = 0.013; Figure 5B). The
same rapid effect was seen after TDZD-8 (1.1 ng/0.5 ul/side;
treatment: F(1,132) = 0.51, p = 0.488; time: F(11,132) = 9.42,
p < 0.0001; treatment x time: F(11,132) = 3.38, p = 0.0004;
Figure 5C). Bilateral administration of amphetamine (1.8 ng/0.5
ul/side) in the striatum, in contrast, rather stimulated locomotor
activity (treatment: F(1,66) = 0.71, p = 0.431; time: F(11,66) = 6.68,
p< 0.0001; treatment x time: F(11,66) = 1.90, p= 0.054; Figure 5E),
and TDZD-8 (1.1 ng/0.5 ul/side) had no effect at all (treatment:
F(1,132) = 0.04, p = 0.843; time: F(11,132) = 9.72, p < 0.0001;
treatment x time: F(11,132) = 0.54, p = 0.870; Figure 5F).
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These observations support the idea that the mPFC as a part
of the activity controlling system (Carlsson and Carlsson, 1989)
is involved in the paradoxical calming effect of amphetamine in
LAB mice.
The Action of Amphetamine in LAB Mice is
Sensitive to NMDA Receptor Signaling in a
GSK3β-Dependent Manner
Since dopamine and norepinephrine are unlikely to be causally
involved in the calming effect of amphetamine at the level of
the mPFC (Figure 2), we studied possible interactions between
amphetamine and glutamate signaling. Previous studies have
suggested such a possibility (Anderzhanova et al., 2001). To this
end, we used a combined treatment of amphetamine and NMDA
receptor blocker MK-801.
In the Experiment 8.1 MK-801 (0.3 mg/kg) injected alone
increased locomotor activity both in HAB and LAB mice. Two-
way ANOVA (time, treatment) of changes in absolute levels
of the distance traveled showed in HAB mice significance of
treatment: F(1,180) 31.13, p = 0.0008; time F(15,180) = 21.22,
p < 0.0001; treatment x time: F(15,180) = 15.31, p < 0.0001. In
LAB mice two-way ANOVA revealed treatment: F(1,165) = 35.02,
p = 0.0001; time F(15,165) = 10.71, p < 0.0001; treatment x
time: F(15,165) = 23.02, p < 0.0001; Figure 6A inset). Since
the effect of the drug can be hindered by the difference
in the basal activity we also analyzed relative changes in
the locomotion under MK-801 treatment. The analysis of
normalized data confirmed the elevation in locomotor activity
by MK-801 both in HAB mice (two-way ANOVA, treatment:
F(1,180) = 236.0, p < 0.0001; time F(15,180) = 14.20, p < 0.0001;
treatment x time: F(15,180) = 23.97, p = 0.0004) and LAB mice
(treatment: F(1,165) = 3.83, p = 0.076; time F(15,165) = 3.58,
p < 0.001; treatment x time: F(15,165) = 9.37, p < 0.0001).
Relative to the basal levels, MK-801 induced less pronounced
elevation in the locomotor activity in LAB mice in comparison
to HAB mice (two-way ANOVA: line: F(1,165) = 14.10,
p = 0.003; time: F(15,165) = 17.87, p < 0.0001; line x time:
F(15,165) = 3.03, p < 0.0001; Figure 6A). This difference
cannot be ascribed to divergence in habituation to the OF.
When saline is injected, HAB, but not LAB, mice show a
persistent decrease in locomotor activity (two-way ANOVA,
line: F(1,185) = 33.97, p < 0.0001; time: F(15,165) = 24.30,
p < 0.001; line x time: F(15,165) = 7.38, p < 0.0001). In
the Experiment 8.2 by microdialysis means we have shown
that pretreatment (−20 min) with MK-801 (0.3 mg/kg, i.p.)
did not facilitate amphetamine-induced dopamine release in
the mPFC of LAB mice, whereas stimulated release in HAB
mice (two-way ANOVA, line: F(1,24) = 3.27, p = 0.048; time:
F(8,24) = 1.31, p = 0.28; line x time: F(8,27) = 1.16, p = 0.32;
Figure 6B, right panel). (The apparent decrease in dopamine
release in LAB mice after MK-801 pretreatment compared to
amphetamine given alone failed to reach the level of statistical
significance).
In the distinct cohort of LAB mice (Experiment 9.1)
MK-801 (0.3 mg/kg) pretreatment (−20 min) restored the
hyperlocomotion in amphetamine-treated (1 mg/kg, i.p.) LAB
mice (two-way ANOVA: treatment: F(1,165) = 9.09, p = 0.0032;
FIGURE 6 | MK-801 shows different activities in LAB and HAB mice
(A). Relative increase in locomotor activity induced by the NMDA receptor
antagonist MK-801 is more pronounced in HAB (triangles) than in LAB (circles)
mice. The dashed lines mark the moments of saline or MK-801 (0.3 mg/kg,
i.p.) administration. The inset graph represents changes in the absolute values
of the distance traveled. **p < 0.01, ***p < 0.001). (B). As revealed by in vivo
microdialysis, pre-treatment (−20 min) with MK-801 facilitates dopamine
release in the mPFC of HAB (triangles), but not of LAB (circle), mice. The
dashed lines mark the moments of amphetamine (1 mg/kg, i.p.) and
MK-801 (0.3 mg/kg, i.p.) administrations. *p < 0.05 vs. LAB mice.
time: F(15,165) = 12.22, p < 0.0001; treatment x time:
F(15,165) = 8.25, p < 0.0001; Figure 7A). MK-801 administered
at the same time with amphetamine (+0 min) abolished the
amphetamine calming effect (two-way ANOVA: treatment:
F(1,265) = 18.63, p = 0.0004, time: F(15,265) = 30.35, p < 0.0001;
treatment x time: F(15,265) = 6.33, p < 0.0001; Figure 7B).
Post-treatment (+20 min) with MK-801 (0.3 mg/kg, i.p.) in
amphetamine- (1 mg/kg, i.p.) treated LAB mice, however,
failed to interfere with its calming effect (two-way ANOVA:
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FIGURE 7 | Amphetamine action in LAB mice interfere with NMDA
receptor signaling (A). Pre-treatment (−20 min) with MK-801 abolishes
amphetamine effect on the locomotor activity in LAB mice. The dashed lines
mark the moments either of saline and amphetamine (1 mg/kg, i.p.) or
MK-801 (0.3 mg/kg, i.p.) and amphetamine (1 mg/kg, i.p.) administration.
**p < 0.01. (B). Co-treatment with MK-801 counteracts the amphetamine
calming effect in LAB mice. The dashed lines mark the moments of either
saline + amphetamine (1 mg/kg, i.p.) or MK-801 (0.3 mg/kg, i.p.) +
amphetamine (1 mg/kg, i.p.) administration. ***p < 0.001. (C). MK-801
post-treatment (+20 min) did not interfere with amphetamine action. The
dashed lines mark the moments of amphetamine (1 mg/kg, i.p.) and MK-801
(0.3 mg/kg, i.p.) injections. (D). Decrease in the phospho-Ser9-GSK3β levels
in the mPFC of LAB (n = 5/5) mice 60 min after MK-801 (0.3 mg/kg, i.p) and
amphetamine (1 mg/kg, i.p.) co-treatment and coinciding with OF exposure.
*p < 0.05 vs. amphetamine + saline. (E). Representative Western blots for the
analysis of GSK3β, pGSK3β protein levels in LAB mice. Bands include
samples both from amphetamine + saline- and amphetamine +
MK-801-treated animals. (F). MK-801 pre-treatment (−20 min) effectively
collapses the calming effect of LiCl. The dashed lines mark the moments of
MK-801 (0.3 mg/kg, i.p.) and LiCl (100 mg/kg, i.p.) injections. ***p < 0.0001.
(G). MK-801 does not interfere with the activity of the pure GSK3β inhibitor
TDZD-8 in its ability to modulate locomotor activity in LAB mice. The dashed
lines mark the moments of either MK-801 (0.3 mg/kg), saline + TDZD-8
(20 mg/kg, i.p.) or MK-801 (0.3 mg/kg, i.p.) + TDZD-8 (20 mg/kg, i.p.)
administration. Since there was no difference between saline and 0.5%
DMSO treatment, results for both vehicle-treated groups were pooled
together. ***p < 0.001, n.s. non significant. (H). Hypothetical scenario:
amphetamine effects on GSK3β comprise NMDA receptor-mediated kinase
slowdown (due to glutamate release) rather than any direct effect. This
pathway, unidentified in details, is uniquely activated in the mPFC of LAB mice
and leads to GSK3β inhibition. Hypofunction of NMDA receptors might be a
permissive cause of this pathway activation.
treatment: F(1,180) = 4.10, p = 0.166; time: F(1,15) = 42.74,
p < 0.0001; treatment x time: F(1,180) = 1.87, p = 0.722;
Figure 7C).
Amphetamine (1 mg/kg) and MK-801 (0.3 mg/kg, i.p.) co-
treatment resulted in a decrease in amphetamine-driven changes
in phosphorylation of GSK3β in the mPFC 60 min after injection
(Experiment 9.2) (t(8)= 3.12, R2= 0.564, p = 0.012; Figures 7D,E).
MK-801 (0.3 mk/kg, i.p.) pre-treatment prevented the
calming effect of non-selective GSK3β inhibitor LiCl
(100 mg/kg, i.p.) in LAB mice (Experiment 9.3) (two-
way ANOVA: treatment: F(1,150) = 8.10, p = 0.057; time:
F(1,15) = 12.21, p < 0.0001; treatment x time: F(1,150) = 16.30,
p < 0.0001; Figure 7F). In contrast, MK-801 (0.3 mg/kg,
i.p.) co-administered with the selective GSK3β inhibitor
TDZD-8 (20 mg/kg, i.p.) (Experiment 9.4) failed to prevent its
calming effect (two-way ANOVA, treatment x time: treatment:
F(1,270) = 0.264, p = 0.614; time: F(15,270) = 79.00, p < 0.0001;
treatment x time: F(15,270) = 7.005, p < 0.0001; Figure 7G.
It is know that in addition to direct inhibition of GSK3β
activity lithium interacts with upstream factors of GSK3β
phosphorylation. Therefore, MK-801 action likely targets
upstream pathway(s) of GSK3β activity regulation.
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Since both the dynamics and magnitude of hyperlocomotion
mitigation in LAB mice were similar after systemic
administration of amphetamine, and TDZD-8 (see Figure 4A),
the differences in MK-801-amphetamine vs. MK-801-TDZD-8
interaction cannot be explained by insufficiency of amphetamine.
Taken together, the behavioral and molecular data suggest an
interaction of amphetamine and NMDA receptor signaling
upstream of GSK3β activity in mediating amphetamine
calming effect.
Discussion
We examined the neurochemical and molecular signature of
the amphetamine calming effect in LAB mice, which are
characterized by the locomotor hyperactivity and cognitive
impairment resembling an ADHD-like endophenotype (Yen
et al., 2013). Our findings suggest that changes in dopamine and
norepinephrine release in the mPFC and the striatum in LAB
mice are unlikely involved in the calming action of amphetamine.
Instead, we provide evidence that amphetamine actions involve
inhibition of GSK3β at the level of themPFC and interaction with
NMDA receptor signaling.
We employed a line comparison strategy to identify the
signature of the calming amphetamine effect in LAB mice.
A set of behavioral and microdialysis experiments render it
highly unlikely that changes in monoamine release play a major
role in the line-specific hyperactivity and the calming effect of
amphetamine: First, LAB mice showed lower, but not higher
basal dopamine levels in the striatum (Figure 2D) compared to
HAB mice. This not only corroborates findings in spontaneously
hypertensive hyperactive rats (Russell et al., 1998; Russell, 2002),
but speaks against the hypothesis that high basal dopamine levels
are causally involved in ADHD-like hyperactivity (Waldman
et al., 1998; Gainetdinov et al., 1999).
Second, both amphetamine and methylphenidate cause a
similar increase in the dopamine and/or norepinephrine levels
in LAB and HAB mice despite the line-specific difference
in behavior (increased locomotion in HAB vs. decreased
locomotion in LABmice after amphetamine treatment compared
to increased locomotion in both lines after methylphenidate
treatment). The similar dynamics of neurochemical and
behavioral changes after methylphenidate are consonant with
an involvement of increased dopamine and/or norepinephrine
signaling in the increased locomotion observed in both LAB
andHABmice. The divergent neurochemical (transient increase)
and behavioral (sustained decrease) changes after amphetamine
treatment in LAB mice, in contrast, argue against a causal
relationship between an amphetamine-induced monoamine
release and a paradoxical calming effect (Figures 1, 2). There
are few reports of methylphenidate ineffectiveness (30--40%)
in treatment of hyperactivity in kids (Winsberg et al., 1980;
Pelham et al., 1999; Gerwe et al., 2009). At the same time
amphetamine effective in a majority of cases (90%) (Pliszka
et al., 2000). Therefore, differential response to amphetamine
and methylphenidate in clinic may serve for a better diagnosis
either to differentiate co-morbid disorders or the ADHD
presentations.
Third, compared to HAB mice, MK-801 pre-treatment failed
to facilitate amphetamine-induced dopamine release in the
mPFC of these animals, but at the same time prevented from
changes in the locomotor activity in LAB mice (Figures 6B,
7A,B). This serves as an additional proof of dopamine-
independent hyperactivity mitigation in LAB mice and points
on possible changes in the NMDA receptor-dependent activity
of the mPFC.
Forth, neuroleptic haloperidol, the dopamine D2 receptor
antagonist, decreased locomotion in LAB, NAB, and HAB
mice to the same extent, induced catalepsy in LAB mice (in
contrast to amphetamine), and elicited comparable changes
in the dopamine and HVA levels in the mPFC of LAB
and HAB mice (Figure 3), suggesting unaltered D2 receptor
signaling in LAB mice. Finally, the lack of line differences in
phosphorylation of GSK3β between saline-treated LAB, NAB,
and HAB mice (Figure 4F) points towards intact regulation
of the β-arrestin2/Akt/GSK3β complex at basal conditions
(Beaulieu et al., 2005), and undisturbed dopamine D2 receptor-
mediated signaling in LAB mice.
Mitigation of hyperactivity by amphetamine in LAB mice
coincided with an increase in GSK3β phosphorylation both
in the mPFC and in the striatum (Figures 4G,H). This
effect was line-specific only at a level of the mPFC in which
neither NAB nor HAB mice showed similar changes. This
suggested that the inhibition of GSK3β activity in the mPFC
contributes to the calming effects of amphetamine. In mice
with normal locomotor activity, an increase in the brain
GSK3β phosphorylation in the striatum and the mPFC
may be observed as early as 15 min after amphetamine
given systemically, whereas GSK3β phosphorylation is
decreased in the striatum 60--90 min after amphetamine
administration (Svenningsson et al., 2003; Beaulieu et al.,
2005). However, Akt-independent increase in GSK3β
phosphorylation in the mPFC was shown after recurrent
amphetamine administration in a model of amphetamine-
induced psychomotor sensitization. This phenomenon may
involve activation of a short-cut GSK3β--β-arrestin2 feedback
(Mines and Jope, 2012).
The short-term mitigation of hyperactivity resulting from
local microinjections of amphetamine and TDZD-8 in themPFC,
but not in the striatum of LAB mice (Figure 5) supports the role
of mPFC in the observed pharmacological phenomenon. In order
to avoid drugs being spread across the structures, we applied low
doses that probably resulted in the rapid and non-lasting drug
effect. The transient effect of microinjections compared to the
results of systemic treatment can be also explained considering
the difference in the pharmacokinetics of drugs at local and i.p.
administration.
Currently, we can only speculate about the way how
the selective decrease in GSK3β activity in the mPFC is
translated into behavior. Since the majority of mPFC neurons
(70--75%) are glutamatergic neurons, it is tempting to assume
that the prominent molecular changes are mediated by
alterations in the projecting glutamatergic neurons of the
mPFC. An alternative scenario is taking into account the
differences in pharmacodynamic aspects of amphetamine and
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methylphenidate action (Calipari et al., 2015). In contrast to
methylphenidate, amphetamine targets the DAT and other
monoamine transporters, pumps the neurotransmitters out of
the terminal, but does not block their uptake. Amphetamine
modulates the phasic release of dopamine, inhibits vesicular
monoamine transporter type 2 and monoamine oxidase. Its
metabolites may also contribute to the profile of amphetamine
actions (Sulzer, 2011). In addition, amphetamine changes the
performance of amino acid transporters (Del Arco et al., 1999),
which results in an increase in the extracellular glutamate levels
(Anderzhanova et al., 2001). As has been recently reported, LAB
and HAB mice are strictly different in the expression of proteins
involved in the regulation of the glutamatergic and GABAergic
neurotransmission at the level of the cingulate cortices (Filiou
et al., 2011; Iris et al., 2014). Moreover, a lower plasma level
of glutamate was found in LAB mice (Zhang et al., 2011).
Together, these observations support the idea of a possible
imbalance of the excitatory and inhibitory neurotransmission
in LAB mice in general. Interestingly, a disturbance in the
glutamatergic neurotransmission was proposed as a mechanism
mediating hyperactivity in DAT-KO mice (Gainetdinov et al.,
2001).
Given the fact that amphetamine may cause glutamate
release, our observations provide a mechanistic explanation
for the specific amphetamine action in LAB mice. The
relatively small increase in locomotor activity in LAB mice
after MK-801 systemic administration in comparison to HAB
mice (Figure 6A) and the lack of its facilitating effect
on amphetamine-evoked dopamine release in the mPFC
(Figure 6B) point to innate changes in NMDA receptor-
mediated activity in these animals (Duncan et al., 2002). The
interpretation of our behavioral data on MK-801 activity may
be limited due to difference in the basal locomotor activity
between LAB and HAB mice. In fact, the normalization
algorithm we applied to compare MK-801 effect between lines
may potentially lead to the drug effect overestimation. Thus,
original data show that LAB mice develop higher absolute
locomotor activity after MK-801 administration than HAB
mice. Nonetheless, a summation of the basal activity and
MK-801 induced effect may be achieved in LAB mice due
to the same function (constitutional or antagonist-induced
decrease in NMDA receptor activity). Our consideration that
the basal hyperlocomotion and diminished relative effect of
MK-801 in LAB mice have same nature is supported by our
neurochemical and molecular data. A possible hypofunctionality
of NMDA receptors in GABA-ergic cortical neurons (Corlett
et al., 2011) may underlie psychotic traits of the endophenotype
representing an ADHD-mania-schizophrenia continuum (Yen
et al., 2013). Our findings of differentially timed MK-801
and amphetamine treatment (Figures 7A,B,C) and lack of
TDZD-8 and amphetamine interaction (Figure 7G) suggest
that amphetamine directs its action at GSK3β in the mPFC
via a pathway, which depends on upstream NMDA receptor-
mediated quasi-metabotropic signaling (Figure 7H). This
NMDA receptor-mediated GSK3β activity regulation may be
independent of pathways forcing Akt phosphorylation at the
Ser308. Preliminary data show that the Thr473 phosphorylation
site is rather engaged, since we have observed a line x structure-
dependent correlation between changes in the levels of phospho-
Thr473-Akt and phospho-Ser9-GSK3β under amphetamine
treatment.
In conclusion, neither the hyperactivity in LAB mice
nor the calming effect of amphetamine can be ascribed to
changes in dopamine and norepinephrine neurotransmission in
the striatum and the mPFC. Instead, amphetamine-triggered
phosphorylation of GSK3β in the mPFC, but not the striatum,
seems to participate in amphetamine-induced mitigation of
hyperactivity in LAB mice. This calming action of amphetamine
involves a functional interaction with NMDA receptors upstream
of GSK3β. From a translational perspective, our data suggest
GSK3β as a target for pharmacotherapy of disorders from the
ADHD-mania-schizophrenia continuum.
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